Camrelizumab (SHR-1210) treatment for recurrent hepatocellular carcinoma after liver transplant: A report of two cases

Q2 Medicine Liver Research Pub Date : 2022-06-01 DOI:10.1016/j.livres.2021.06.002

Tianxing Dai , Qing Yang , Yingcai Zhang , Linsen Ye , Hua Li , Shuhong Yi , Wei Liu , Yang Yang , Guoying Wang

{"title":"Camrelizumab (SHR-1210) treatment for recurrent hepatocellular carcinoma after liver transplant: A report of two cases","authors":"Tianxing Dai , Qing Yang , Yingcai Zhang , Linsen Ye , Hua Li , Shuhong Yi , Wei Liu , Yang Yang , Guoying Wang","doi":"10.1016/j.livres.2021.06.002","DOIUrl":null,"url":null,"abstract":"<div><p>Immune checkpoint inhibitors are generally contraindicated for post-transplant patients. However, we report two patients with metastatic hepatocellular carcinoma (HCC) treated with camrelizumab (SHR-1210), an anti-programmed cell death 1 (PD-1) agent, after liver transplant. Before undergoing immunotherapy, both patients underwent liver allograft biopsy and obtained negative PD-L1 expression in tumor and liver graft specimens by immunohistochemistry. Then, camrelizumab (200 mg) was administered once every 3 weeks. During immunotherapy, the targeted therapy was continued, and the immunosuppression regimen was adjusted to a low-dose level. No graft rejection or other severe adverse reactions were observed. The disease remained stable (SD, mRECIST) for 3 months in one patient and 10 months in the other. Therefore, camrelizumab may have safety and potential benefits in advanced HCC after liver transplant.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 2","pages":"Pages 111-115"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.livres.2021.06.002","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2542568421000428","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Immune checkpoint inhibitors are generally contraindicated for post-transplant patients. However, we report two patients with metastatic hepatocellular carcinoma (HCC) treated with camrelizumab (SHR-1210), an anti-programmed cell death 1 (PD-1) agent, after liver transplant. Before undergoing immunotherapy, both patients underwent liver allograft biopsy and obtained negative PD-L1 expression in tumor and liver graft specimens by immunohistochemistry. Then, camrelizumab (200 mg) was administered once every 3 weeks. During immunotherapy, the targeted therapy was continued, and the immunosuppression regimen was adjusted to a low-dose level. No graft rejection or other severe adverse reactions were observed. The disease remained stable (SD, mRECIST) for 3 months in one patient and 10 months in the other. Therefore, camrelizumab may have safety and potential benefits in advanced HCC after liver transplant.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Camrelizumab (SHR-1210)治疗肝移植后复发性肝癌2例报告

免疫检查点抑制剂通常禁止用于移植后患者。然而，我们报告了两例转移性肝细胞癌(HCC)患者在肝移植后使用抗程序性细胞死亡1 (PD-1)药物camrelizumab (SHR-1210)治疗。在接受免疫治疗前，两例患者均行同种异体肝移植活检，通过免疫组化检测肿瘤和肝移植标本中PD-L1表达为阴性。然后，每3周给药一次camrelizumab (200mg)。在免疫治疗期间，继续进行靶向治疗，将免疫抑制方案调整为低剂量水平。未观察到移植排斥反应或其他严重不良反应。1例患者病情稳定(SD, mRECIST) 3个月，另1例患者10个月。因此，camrelizumab在肝移植后晚期HCC中可能具有安全性和潜在益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊